Share Name Share Symbol Market Type Share ISIN Share Description
Hikma Pharmaceuticals LSE:HIK London Ordinary Share GB00B0LCW083 ORD SHS 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +7.00p +0.39% 1,794.50p 1,796.50p 1,798.50p 1,810.00p 1,776.50p 1,785.50p 469,772 16:35:29
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1,433.4 -546.4 -260.1 - 4,332.30

Hikma Pharmaceuticals Share Discussion Threads

Showing 1026 to 1049 of 1050 messages
Chat Pages: 42  41  40  39  38  37  36  35  34  33  32  31  Older
DateSubjectAuthorDiscuss
01/10/2018
08:51
After a pause.....
robertball
17/9/2018
10:22
Barclays reiterate their 1400 guidance today. What are they on?
bantam175
06/9/2018
16:08
Has Pfizer sorted their problems out?
robertball
21/8/2018
13:11
Traded no trades
gerrym two
21/8/2018
13:10
We said HIk would be back at 20 soon...it could get there today !! Will keep going in my view and on the back of a weak or at least a flat market.....what price does it have to get to get back into FT 100... or maybe it is ??I bought again at 1860p ...trades get the whole way up, my best trades share this year...by a distance.
gerrym two
20/8/2018
09:54
Back into profit with hik and I think there is more to come. Happy days. Suet
suetballs
15/8/2018
13:55
no. who from?
r ball
15/8/2018
13:38
What odds on a possible bid before the share price gets to high I wonder?
bantam175
15/8/2018
12:38
so good results on the back of Pfizer issues.
r ball
15/8/2018
09:52
Brokers too embarrassed to put heads above water atm. Especially Barclays with their underweight 1100 target just 5 days ago. Return to ftse100 could see these at £25 and higher still if the FDA approval goes through next year. All imho dyor etc
bantam175
15/8/2018
08:49
results exceeded expectations...50k buy just went through...upgrades from brokers?
pre
15/8/2018
08:30
Generic drugmaker Hikma Pharmaceuticals issued its interim results for the six months ended 30 June on Wednesday, reporting an 11% improvement in group revenue to $989m, or 10% in constant currency. The FTSE 250 company said its operating profit for the period was $174m, up 54%, while core group operating profit rose 22% to $214m, or 23% in constant currency. Core basic earnings per share totalled 61.4 US cents, up 35%, and 38% in constant currency, with basic earnings per share rising 53% to 44.0 cents, or 57% in constant currency. Cash flow from operations reached $185m. Hikma said its net debt fell to $501m, from $546m at the end of December, with “healthy”; leverage ratios maintained. Its board declared an interim dividend of 12 cents per share, up from 11 cents per share a year ago. The company also raised its guidance for the injectables and generics businesses, and reiterated it for the branded business. “I am pleased with our first half performance, with each of our three business segments achieving revenue and, importantly, profit growth,” said Hikma chief executive officer Siggi Olafsson. “Our injectables business continues to demonstrate resilience. “Our broad portfolio, extensive manufacturing capabilities and geographic footprint are enabling us to respond quickly to changing market dynamics and grow our market share.” Olafsson said that in the generics business, Hikma was “successfully” driving demand for its “more differentiated”; in-market products, and was making progress reducing its cost base. “We achieved good results in the branded business, taking into consideration the usual seasonality. “In the first half, we renewed our focus on advancing our pipnlinee, enhancing our corporate research and development team and accelerating new projects. “More broadly, we are strengthening key functions across the group and bringing new capabilities to ensure we have the right teams in place to take the business forward.” Hikma’s performance in the first half exceeded the board’s expectations, Olafsson said, and it was reportedly “pleased”; to be able to raise its guidance for both the injectables and generics businesses for the full year. “The measures we have taken and investments we have made across the group over the past year are delivering results, but we still have work to do. “Our markets are competitive and we don't expect the same demand for some of our injectable products to continue into 2019,” Siggi Olafsson explained. “This means we must remain focused on strengthening our customer relationships, improving profitability and advancing our pipeline to ensure future growth.”
broadwood
15/8/2018
08:14
congratulations!
eentweedrie
15/8/2018
08:11
So I was right to say last night that results will prove Numis was wrong to advice its investors to sell.
karateboy
15/8/2018
08:04
auction is taking a while
eentweedrie
15/8/2018
08:01
Interim is increased from 11 cents to 12 cents.
karateboy
15/8/2018
07:38
Our performance in the first half exceeded our expectations and we are pleased to be able to raise our guidance for both our Injectables and Generics businesses for the full year.
broadwood
15/8/2018
07:17
Results far and away better than expected. Been accumulating (selling peaks buying troughs) for a while. Holding tight now for the time being. £20ps a likely possibility imo. imho, dyor etc etc
bantam175
15/8/2018
07:06
Wish I'd bought more when under a tenner. Hindsight...
richtea2517
14/8/2018
22:58
Should prove how wrong was Numis.
karateboy
14/8/2018
21:46
wonder what tomorrow will bring
eentweedrie
13/8/2018
19:21
A few decent buys at the close hope they haven't had the nod
joshuam
10/8/2018
10:16
I like Hikma long term but I don't hold any stock through results after a few bitter experiences where stops have been useless. So I'll sell next week and re buy when I see the right chart spot. If I miss a big rise on results day - es la vida!
jgoold
10/8/2018
09:25
http://www.proactiveinvestors.co.uk/companies/news/202578/numis-cuts-hikma-pharma-to-hold-from-add-on-valuation-grounds-ahead-of-upcoming-interims
bantam175
Chat Pages: 42  41  40  39  38  37  36  35  34  33  32  31  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V: D:20181022 21:59:54